{"article_title": "Amgen Demands Injunction In Biosimilar Suit", "article_keywords": ["set", "suitlaw360", "demands", "injunction", "amgen", "soon", "version", "sandoz", "york", "suit", "biosimilar", "view"], "article_url": "http://www.law360.com/articles/619303/amgen-demands-injunction-in-biosimilar-suit", "article_text": "Amgen Demands Injunction In Biosimilar Suit\n\nLaw360, New York (February 6, 2015, 2:54 PM ET) -- Amgen Inc. asked a California federal judge on Friday to grant it a preliminary injunction in its fight with Sandoz Inc. over a biosimilar version of Neupogen, arguing that Sandoz\u2019s market entry will be illegal and will irreparably harm Amgen and that an injunction is in the public interest.\n\n\n\nThe biopharmaceutical company said in its motion that Sandoz can begin marketing its product as soon as March 8, but that the hearing on cross-motions for judgment is only set for March 2. Amgen contends that Sandoz...\n\nTo view the full article, register now.", "article_metadata": {"description": "Amgen Inc. asked a California federal judge on Friday to grant it a preliminary injunction in its fight with Sandoz Inc. over a biosimilar version of Neupogen, arguing that Sandoz&rsquo;s market entry will be illegal and will irreparably harm Amgen and that an injunction is in the public interest.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/619303/amgen-demands-injunction-in-biosimilar-suit", "csrf-token": "QXRLfcLhn7pPjmJOuftP6F/PVaTVM35TPjsahJCgK7ryiqTkBXnbxzdJYzL2fckDKBpBU0SoVNN80s48Equ5BQ==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/619303/amgen-demands-injunction-in-biosimilar-suit", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Amgen Demands Injunction In Biosimilar Suit - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "Amgen Demands Injunction In Biosimilar SuitLaw360, New York (February 6, 2015, 2:54 PM ET) -- Amgen Inc. asked a California federal judge on Friday to grant it a preliminary injunction in its fight with Sandoz Inc. over a biosimilar version of Neupogen, arguing that Sandoz\u2019s market entry will be illegal and will irreparably harm Amgen and that an injunction is in the public interest.\nAmgen contends that Sandoz...To view the full article, register now.\nThe biopharmaceutical company said in its motion that Sandoz can begin marketing its product as soon as March 8, but that the hearing on cross-motions for judgment is only set for March 2."}